This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Amgen-Horizon deal shouldn't be enjoined pending US FTC review because of lack of overlaps, trade groups tell court

( August 25, 2023, 14:03 GMT | Official Statement) -- MLex Summary: Enjoining the merger of Amgen and Horizon pending a US Federal Trade Commission administrative trial is unnecessary because the lack of overlap between the two firms means "post-merger relief will not need to 'unscramble' any material mixing of productive assets," while "an injunction would continue to delay the merger’s potential benefits," the Biotechnology Innovation Organization, Illinois Manufacturers Association, Chicagoland Chamber of Commerce and Illinois Biotechnology Innovation Organization said in an amicus brief in Illinois federal court.See document below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login